AU2002331898A1 - Induction of brown adipocytes by transcription factor nfe2l2 - Google Patents

Induction of brown adipocytes by transcription factor nfe2l2

Info

Publication number
AU2002331898A1
AU2002331898A1 AU2002331898A AU2002331898A AU2002331898A1 AU 2002331898 A1 AU2002331898 A1 AU 2002331898A1 AU 2002331898 A AU2002331898 A AU 2002331898A AU 2002331898 A AU2002331898 A AU 2002331898A AU 2002331898 A1 AU2002331898 A1 AU 2002331898A1
Authority
AU
Australia
Prior art keywords
nfe2l2
induction
transcription factor
brown adipocytes
adipocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002331898A
Inventor
Leslie P. Kozak
Jong S. Rim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University and Agricultural and Mechanical College
Original Assignee
Louisiana State University and Agricultural and Mechanical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University and Agricultural and Mechanical College filed Critical Louisiana State University and Agricultural and Mechanical College
Publication of AU2002331898A1 publication Critical patent/AU2002331898A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
AU2002331898A 2001-09-24 2002-09-24 Induction of brown adipocytes by transcription factor nfe2l2 Abandoned AU2002331898A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32440001P 2001-09-24 2001-09-24
US60/324,400 2001-09-24
PCT/US2002/030266 WO2003026576A2 (en) 2001-09-24 2002-09-24 Induction of brown adipocytes by transcription factor nfe2l2

Publications (1)

Publication Number Publication Date
AU2002331898A1 true AU2002331898A1 (en) 2003-04-07

Family

ID=23263411

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002331898A Abandoned AU2002331898A1 (en) 2001-09-24 2002-09-24 Induction of brown adipocytes by transcription factor nfe2l2

Country Status (2)

Country Link
AU (1) AU2002331898A1 (en)
WO (1) WO2003026576A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7576052B2 (en) 2003-10-17 2009-08-18 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
WO2006108023A2 (en) * 2005-04-04 2006-10-12 Joslin Diabetes Center, Inc. Methods and compositions for modulating necdin function
US20100150885A1 (en) 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CN103601792B (en) 2007-06-04 2016-06-29 协同医药品公司 It is effective to the guanylate cyclase agonist of gastrointestinal dysfunction, inflammation, cancer and other diseases treatment
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
MX2011004258A (en) 2008-10-22 2011-06-01 Merck Sharp & Dohme Novel cyclic benzimidazole derivatives useful anti-diabetic agents.
JP5557845B2 (en) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション Novel cyclic benzimidazole derivatives useful as antidiabetic agents
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
KR20150075120A (en) 2011-02-25 2015-07-02 머크 샤프 앤드 돔 코포레이션 Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
RU2015106909A (en) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. ANTI-DIABETIC TRICYCLIC COMPOUNDS
MX2015010935A (en) 2013-02-22 2015-10-29 Merck Sharp & Dohme Antidiabetic bicyclic compounds.
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CN105764916B (en) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 Ultra-pure agonists of guanylate cyclase C, methods of making and using the same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CA2926685A1 (en) 2013-10-09 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4495787B2 (en) * 1997-05-30 2010-07-07 ダナ−ファーバー キャンサー インスティテュート インク． PGC-1, a new brown fat PPAR ▲ bottom γ ▼ coactivator
JP2002536009A (en) * 1999-02-09 2002-10-29 レキシコン・ジェネティクス・インコーポレーテッド Human uncoupling protein and polynucleotide encoding the same

Also Published As

Publication number Publication date
WO2003026576A3 (en) 2003-06-26
WO2003026576A2 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
AU2002331898A1 (en) Induction of brown adipocytes by transcription factor nfe2l2
AU2002360988A1 (en) Adhesion inhibition of moulds
AU2002223504A1 (en) Heterologous expression of taxanes
AU2003303250A1 (en) Quantification of operational risks
AU2001245989A1 (en) Preparation of epothilone intermediates
AU2002245293A1 (en) Integrated transformer
AU2002341542A1 (en) Transcription factors of cereals
AU2002326949A1 (en) Method for the inhibition of methanogenesis
AU2003275056A1 (en) Novel lapacho compounds and methods of use thereof
AU2002358133A1 (en) Winding spindle having an increased natural frequency
GB0024475D0 (en) Induction hardening of rotational components
AU2002362108A1 (en) Digital-to-phase converter with extended frequency range
AU2002318449A1 (en) Isoform of castor oleate hydroxylase
AU2002303390A1 (en) Induction of apoptosis by cellular stress
AU2002337053A1 (en) Measuring transformer
AU2002361763A1 (en) Method of reducing angiogenesis
AU2002360394A1 (en) Facilitation of rna interference
AU2003296313A1 (en) Modulation of fetoprotein transcription factor expression
AU2003299137A1 (en) Inhibition of metallo-beta-lactamase
AU2003222975A1 (en) Induction furnace
AU2003283246A1 (en) Inductive flowmeter
GB0100151D0 (en) Methods of sputtering
AU2002360974A1 (en) Novel use of alloys
AUPR539601A0 (en) Method of magnetic field measurement
GB0102087D0 (en) Transcription factor

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase